SBC Medical Appoints Dr. Ewen Chee as Lead Doctor for Asia Strategy to Accelerate Global Expansion

 (BUSINESS WIRE)--SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced that Dr. Ewen Chee, founder of Singapore’s leading aesthetic medical company Aesthetic Healthcare Holdings (“AHH”), has been appointed President of AHH and Lead Doctor for Asia Strategy at SBC Medical Group. In this role, Dr. Chee will support physician recruitment and training across the Asia-Pacific region, contributing to SBC’s global strategy.

Singapore is internationally recognized as a trusted destination for aesthetic medicine, supported by its robust medical infrastructure and stringent regulatory environment. Leveraging its geographic advantages, the country attracts patients from neighboring Indonesia, Malaysia, Thailand, and Vietnam, and has developed into a center of medical tourism, establishing itself as the “Aesthetic Medicine Hub of Asia.”

In this environment, Dr. Chee has accumulated more than 20 years of clinical experience and is regarded as a pioneer of aesthetic medicine in Singapore. In 1999, he founded The Chelsea Clinic, among the first to introduce IPL treatments domestically. He has served as an international trainer in various types of fillers, lasers, botulinum toxin, and thread lifts. In addition, he acted as Co-Chair of the Asia-Pacific Thread Lift Meeting (APEM), earning broad international recognition through education and speaking activities. Dr. Chee is also a certified physician of the American Academy of Aesthetic Medicine (AAAM), with his expertise presented at numerous international congresses and workshops.

Looking ahead, SBC will leverage Dr. Chee’s expertise and AHH’s brand portfolio to establish a scalable platform for physician recruitment and training across Asia-Pacific. Anchored by its group purpose, “Contributing to the happiness of people worldwide through medical innovation,” the Group is building a foundation for sustainable growth and expanding its leadership position in the global aesthetic medicine industry.

About Aesthetic Healthcare Holdings Pte. Ltd.

AHH is based in Singapore and operates aesthetic medical clinics, family clinics, and quick facial aesthetics outlets. The founder, Dr. Ewen Chee, is known as one of the pioneers in the field of aesthetic medicine in Singapore and is a co-chair of the first Asia Pacific Thread Lift Conference (APEM) and a board-certified physician by the American Academy of Aesthetic Medicine. He is a frequent speaker at international conferences and workshops, and his expertise and knowledge have been featured in numerous scientific publications.

AHH Major brands and number of clinics:

The Chelsea Clinics (2 locations) https://chelseaclinic.com.sg/

Gangnam Laser Clinic (1 location) https://www.gangnamlaser.com/

SkinGo! (16 locations) https://skingo.sg/

Family clinics (2 locations)

About SBC Medical

SBC Medical, headquartered in Irvine, California and Tokyo, Japan, owns and provides management services and products to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchisee clinics, including but not limited to advertising and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and training), booking reservations for franchisee clinic customers, assistance with franchisee employee housing rentals and facility rentals, construction and design of franchisee clinics, medical equipment and medical consumables procurement (resale), the provision of cosmetic products to franchisee clinics for resale to clinic customers, licensing of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchisee clinic’s customer rewards program (customer loyalty point program), and payment tools for the franchisee clinics.

For more information, visit https://sbc-holdings.com/

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250825055997/en/

Permalink

https://www.aetoswire.com/en/news/2508202548573

Contacts

SBC Medical Group Holdings Incorporated (Asia)

Hikaru Fukui / Head of Investor Relations E-mail: ir@sbc-holdings.com

Akiko Wakiyama / Head of Public Relations E-mail: pr@sbc.or.jp

ICR LLC (In the US)

Bill Zima / Managing Partner Email: bill.zima@icrinc.com

 

Incode Joins Experian Partner Ecosystem Strengthening Fraud Prevention Solutions

  COSTA MESA, Calif. - Monday, 25. August 2025 AETOSWire  

Integration strengthens Experian’s Ascend Platform with AI-powered identity verification for faster decisions, stronger identity verification and seamless customer experience

(BUSINESS WIRE) -- Experian today announced the integration of Incode Technologies, Inc. (“Incode”) into the Experian Ascend Platform™. This collaboration will enable seamless, secure and efficient identity validation for over 1,800 global clients across industries including financial services, automotive, healthcare and digital marketing.

Through this partnership, Incode’s advanced identity validation and real-time metadata analysis will be offered as an optional component within Experian’s CrossCore Document Verification suite in North America, with global expansion planned. Incode’s AI-driven technology strengthens Experian’s identity and fraud solutions by verifying and connecting identity elements such as government-issued IDs, facial recognition, liveness checks, and real time metadata.

“This partnership reinforces Experian’s commitment to delivering innovative, secure, and customer-centric solutions,” said Marika Vilen, Senior Vice President of Global Partnerships and Commercialization at Experian. “By integrating Incode’s cutting-edge identity verification technology into the Ascend Platform, we’re empowering organizations to make faster, smarter decisions while tailoring their fraud and risk strategies with unprecedented agility and precision.”

Identity verification is central to Experian’s identity and fraud portfolio, helping organizations combat cybercrime while maintaining a seamless customer experience. This integration provides stronger protection against synthetic identity and application fraud, as well as higher accuracy in detection and workforce identity.

“We’re thrilled to partner with Experian to help power their platform with the most advanced AI identity verification technology on the market,” said Ricardo Amper, Founder and CEO of Incode. “In a world where deepfakes, AI-driven fraud, and agentic AI are evolving at unprecedented speed, improved protections are critical. Together, we’re addressing the most prevalent fraud vectors with unmatched speed, security, and accuracy — while keeping the user experience seamless and intuitive.”

About Experian

Experian is a global data and technology company, powering opportunities for people and businesses around the world. We help to redefine lending practices, uncover and prevent fraud, simplify healthcare, deliver digital marketing solutions, and gain deeper insights into the automotive market, all using our unique combination of data, analytics and software. We also assist millions of people to realise their financial goals and help them to save time and money.

We operate across a range of markets, from financial services to healthcare, automotive, agrifinance, insurance, and many more industry segments.

We invest in talented people and new advanced technologies to unlock the power of data and innovate. As a FTSE 100 Index company listed on the London Stock Exchange (EXPN), we have a team of 25,200 people across 32 countries. Our corporate headquarters are in Dublin, Ireland. Learn more at experianplc.com.

About Incode Technologies, Inc, (“Incode”)

Incode is a global leader in AI-driven identity verification and biometric authentication, empowering organizations to build trust in the digital world. With over ten years of innovation, Incode delivers cutting-edge technology to secure operations and combat fraud across industries.

Experian and the Experian marks used herein are trademarks or registered trademarks of Experian and its affiliates. Other products and company names mentioned herein are the property of their respective owners.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250825234314/en/

Permalink

https://www.aetoswire.com/en/news/25082025848581

Contacts

Michael Troncale

Experian Public Relations

+1 714 830 5462

michael.troncale@experian.com

NIQ's New Business Resiliency Playbook Helps Companies Decode the Market Signals and Shocks That Shape Consumer Behavior

 This first-of-its-kind actionable framework—built on marrying 50 years of economic and consumer behavior trend data—equips brands and retailers with key signals to help them sustain revenue and avoid panic or paralysis.

(BUSINESS WIRE)--NielsenIQ (NIQ) (NYSE: NIQ), a leading consumer intelligence company, today unveiled The Business Resiliency Playbook: Decoding the signals and shocks that shape consumer behavior. The playbook outlines potential impacts of the five most relevant economic scenarios for brands and retailers—including stagflation, recession, and geopolitical shocks—and how the consumers who will shape their businesses are most likely to respond to them. Critically, it highlights how delaying decisions in an unpredictable environment can expose businesses to risk and provides specific actions to help them position for resilience.

“Our goal isn’t to predict the future, but to help organizations develop robust plans that can adapt as conditions evolve,” said Ramon Melgarejo, President of Strategic Analytics & Insights, NIQ. “This playbook empowers leaders to move from reactive to resilient—using real-time consumer intelligence to guide decisions with confidence.”

Key findings include:

• Consumers don’t often differentiate between the causes of economic stress. Whether it’s inflation, job loss, or global conflict, their behavioral responses are strikingly similar. They pull back on discretionary spending, prioritize essentials, and seek value—often turning to private label products or value retailers.
• Despite fluctuating confidence and sentiment in 2025, consumers are continuing to spend overall. For the historically most sensitive categories of Meat, Seafood, Ready-to-Eat Cereal, Household Care, and Sugar & Sweets, overall spending has remained mostly flat (July 2023–June 2025), signaling consumer confidence—at least in the short-term.
• While the consumer responses to stress are similar under the scenarios analyzed, the scale and speed of their response is proportional to the magnitude of the shock. Businesses that strategize with optimal consumer trend data (overlayed with historical performance) are ideally positioned to weather any forthcoming economic headwinds.

“Our data clearly show that the size and scale of an economic ‘shock’ carries more weight than the shock itself,” said Courtenay Verret, VP, Global Thought Leadership, NIQ. “Having robust data sets—early on—will help insulate your organization from strategic misfires and allow you to pivot critical resources toward maximizing revenue and maintaining loyalty and growth.”

Click here to access our business resiliency playbook and framework.

About NIQ

NIQ is a leading consumer intelligence company, delivering the most complete understanding of consumer buying behavior and revealing new pathways to growth. Our global reach spans over 90 countries covering approximately 85% of the world’s population and more than $7.2 trillion in global consumer spend. With a holistic retail read and the most comprehensive consumer insights—delivered with advanced analytics through state-of-the-art platforms—NIQ delivers the Full View™.

For more information, please visit www.niq.com

© 2025 Nielsen Consumer LLC. All Rights Reserved.

NIQ-GENERAL

View source version on businesswire.com: https://www.businesswire.com/news/home/20250825147642/en/

Permalink

https://www.aetoswire.com/en/news/2508202548580

Contacts

Media Contact: media.relations@niq.com

BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million

 SAN CARLOS, Calif. - Monday, 25. August 2025 AETOSWire Print 

Royalty Pharma to acquire rights to BeOne’s royalties on IMDELLTRA® (tarlatamab-dlle) worldwide (ex-China) sales for up to $950 million

IMDELLTRA is a first-in-class DLL-3 targeting bispecific T-cell engager, indicated for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy

 

(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it has entered into an agreement to sell its royalty rights on the worldwide sales, excluding China, of Amgen’s IMDELLTRA® (tarlatamab-dlle) for up to $950 million to Royalty Pharma (Nasdaq: RPRX).

Under the terms of the agreement, BeOne will receive an upfront payment of $885 million, with the option to sell remaining royalties within 12 months for up to $65 million. BeOne will share in a portion of the royalty on annual sales above $1.5 billion, and will maintain royalty and all other rights to other assets under the terms of the existing collaboration with Amgen, including xaluritamig, a first-in-class STEAP1 x CD3 XmAb currently being studied in patients with metastatic castration-resistant prostate cancer (mCRPC).

IMDELLTRA is a first-in-class immunotherapy that binds to both DLL3 on tumor cells and CD3 on T cells, activating T cells to kill DLL3-expressing cells. IMDELLTRA is approved in the United States for patients with extensive-stage small cell lung cancer (ES-SCLC) who have progressed on or after receiving platinum-based chemotherapy.

“Today’s announcement is testament to the value of our long-term collaboration with Amgen, the developer of IMDELLTRA, who recognized the potential of BeOne in advancing their oncology pipeline,” said John V. Oyler, Co-Founder, Chairman and CEO of BeOne. “In the five years since entering into this collaboration, we have executed with purpose in advancing our mission to deliver multiple transformative medicines to more patients worldwide.”

“This agreement meaningfully accelerates value realization for BeOne, while preserving continued participation in the long-term potential of IMDELLTRA,” said Aaron Rosenberg, Chief Financial Officer, BeOne. “A strong balance sheet is a hallmark of the most successful companies in our industry, and this transaction provides increased operational and strategic flexibility as we continue to execute our business strategy for the long term.”

About IMDELLTRA® (tarlatamab-dlle)

IMDELLTRA is a first-in-class immunotherapy that binds to both DLL3 on tumor cells and CD3 on T cells, activating T cells to kill DLL3-expressing cells. This results in the formation of a cytolytic synapse with lysis of the cancer cell. DLL3 is a protein that is expressed on the surface of SCLC cells in the vast majority of patients with SCLC, but is minimally expressed on healthy cells, making it an exciting target.

Tarlatamab is being investigated in multiple studies including DeLLphi-303, a Phase 1b study evaluating tarlatamab in combination with standard of care therapies in first-line ES-SCLC; DeLLphi-304, a randomized Phase 3 trial comparing tarlatamab monotherapy with standard of care chemotherapy in second-line treatment of ES-SCLC; DeLLphi-306, a randomized placebo-controlled Phase 3 trial of tarlatamab following concurrent chemoradiotherapy in limited-stage SCLC; DeLLphi-308, a Phase 1b study evaluating subcutaneous tarlatamab in second line or later ES-SCLC; and DeLLphi-309, a Phase 2 study evaluating alternative intravenous dosing regimens with tarlatamab in second-line ES-SCLC.

About BeOne Medicines

BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of more than 11,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them.

To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding: the total amount of proceeds that BeOne will receive from the sale of IMDELLTRA royalty rights; the exercise of BeOne’s option to sell the remaining IMDELLTRA royalty rights; the benefits of the transaction; and BeOne’s plans, commitments, aspirations, and goals under the heading “About BeOne.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeOne's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne's reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeOne’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law.

To access BeOne media resources, please visit our Newsroom site.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250825210828/en/

Permalink

https://www.aetoswire.com/en/news/2508202548574

Contacts

Investor Contact

Liza Heapes

+1 857-302-5663

ir@beonemed.com

Media Contact

Navneet Miller

+1 857-301-6440

media@beonemed.com

Thoma Bravo Acquires Verint to Join Forces with Calabrio to Create an AI-Driven Customer Experience Powerhouse

MINNEAPOLIS & SAN FRANCISCO - Monday, 25. August 2025

(BUSINESS WIRE) -- Thoma Bravo, a leading software investment firm, announced today that it has entered into a definitive agreement to purchase Verint Systems, Inc. (Nasdaq: VRNT) (“Verint”) in an all-cash transaction reflecting an enterprise value of $2 billion for the company. The transaction is subject to customary closing conditions, including regulatory approvals, and is expected to close before the end of Verint’s current fiscal year, in early 2026. More details on the transaction can be found via Verint’s Investor Relations page and in its regulatory filings.

Following the close of the transaction, Calabrio and Verint will be combined into one company and will be a leading provider of Customer Experience (CX) Automation Solutions to the $50B+ market in which they serve. Together, they will offer an expansive portfolio to advance the critical priorities of CX organizations across the size and complexity spectrum. The combination will create more opportunities for companies to quickly achieve business outcomes in their interactions with customers. Calabrio is fully committed to maintaining and investing in the products that support its installed base and customers’ workflows.

“Together Calabrio and Verint will bring a powerful set of products to accelerate a shared vision: delivering an AI-powered, open CX-platform to customers who are focused on driving strong business outcomes in their operations. As a combined company we are well positioned to lead the industry forward,” said Dave Rhodes, Calabrio CEO.

Mike Hoffmann, a Partner at Thoma Bravo added: “We have been active in the CX space for many years and are excited to bring these two companies together to lead more innovation and growth in the category. Calabrio and Verint both have powerful product portfolios and go-to-market strategies that cover the needs of a wide spectrum of the market. Together, the combined company will have the industry’s broadest CX platform, enabling brands of all sizes to drive transformative, AI-driven outcomes.”

About Thoma Bravo

Thoma Bravo is one of the largest software-focused investors in the world, with approximately $184 billion in assets under management as of March 31, 2025. Through its private equity, growth equity and credit strategies, the firm invests in growth-oriented, innovative companies operating in the software and technology sectors. Leveraging Thoma Bravo’s deep sector knowledge and strategic and operational expertise, the firm collaborates with its portfolio companies to implement operating best practices and drive growth initiatives. Over the past 20+ years, the firm has acquired or invested in approximately 535 companies representing approximately $275 billion in enterprise value (including control and non-control investments). The firm has offices in Chicago, Dallas, London, Miami, New York and San Francisco. For more information, visit Thoma Bravo’s website at thomabravo.com.

About Calabrio

Calabrio is a trusted ally to leading brands. The digital foundation of a customer-centric contact center, the Calabrio ONE workforce performance suite helps enrich and understand human interactions, delivering business outcomes by optimizing every customer interaction. We maximize agent performance, exceed customer expectations, and boost workforce efficiency using connected data, AI-fueled analytics, automated workforce management, and personalized coaching. Only Calabrio ONE unites workforce optimization (WFO), agent engagement, and business intelligence solutions into a cloud-native, fully integrated suite that adapts to your business. Calabrio, Calabrio ONE, and the Calabrio logo are registered trademarks or trademarks of Calabrio, Inc. All other trademarks mentioned in this document are the property of their respective owners. Calabrio operates in Canada under Calabrio Canada, Ltd., based in British Columbia.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250824564235/en/

Permalink

https://www.aetoswire.com/en/news/2508202548579

Contacts

For further information contact

For Thoma Bravo

Megan Frank

+1.212.731.4778

mfrank@thomabravo.com

or

FGS Global

Liz Micci/Abby Farr

ThomaBravo-US@fgsglobal.com

For Calabrio

Dillon Nugent

dillon.nugent@calabrio.com

or

TouchDown PR

Lauren Curley

+1. 617.529.6463

lauren.curley@touchdownpr.com

The Empire State Building Unveils ‘KPOP DEMON HUNTERS’ Music-To-Light Spectacular and Cast Visit, in Partnership with Netflix, CAPE USA, and iHeartMedia

 NEW YORK - 

Stars Arden Cho, May Hong, and singer REI AMI flipped the switch in a special lighting ceremony for the show, that featured the film’s hit song “Golden”

(BUSINESS WIRE) -- The Empire State Building (ESB) announced today that it premiered a Music-to-Light Spectacular to kick off “KPOP DEMON HUNTERS” Golden Weekend on Aug. 22, in partnership with Netflix and the Coalition of Asian Pacifics in Entertainment (CAPE) and with support from iHeartMedia. Earlier that day, the film’s stars Arden Cho, May Hong, and singer REI AMI visited the Empire State Building for a special tower lighting ceremony where they flipped the famous light switch and toured the top NYC attraction.

“Our 'KPOP DEMON HUNTERS’ Music-to-Light Spectacular is a celebration of global culture and creativity right in the heart of New York City,” said Dan Rogoski, senior vice president, observatory general manager at the Empire State Building. “We are so pleased to connect our fans in New York City and around the world with the artists that they love – both real and fictional.”

The music-to-light show debuted that evening at 9 p.m., set to a broadcast of the film’s historic hit and song of the summer, “Golden,” on iHeartMedia New York’s Z100. After the show, the building shined its world-famous tower lights in gold to represent the song.

“KPOP DEMON HUNTERS” is the most-watched Netflix animated original film of all time and second on the Netflix Most Popular Movies list. The song “Golden” – performed by the film’s fictional band Huntr/x, that features vocalists EJAE, AUDREY NUNA, and REI AMI – made history as the first single by a female K-pop artist to reach the top spot on the Billboard Hot 100.

The Empire State Building Music-to-Light Spectacular features thousands of LED lights choreographed by famed lighting designer Marc Brickman and his Tactical Manouevre team.

Text CONNECT to 274-16 to receive real-time updates and information about the Empire State Building’s tower lights.

Hi-res imagery and video of the Music-to-Light Spectacular and cast visit can be downloaded here.

More information about the Empire State Building can be found online.

About the Empire State Building

The Empire State Building, the “World's Most Famous Building," owned by Empire State Realty Trust, Inc. (ESRT: NYSE), soars 1,454 feet above Midtown Manhattan from base to antenna. The $165 million reimagination of the Empire State Building Observatory Experience created an all-new experience with a dedicated guest entrance, an interactive museum with nine galleries, and a redesigned 102nd Floor Observatory with floor-to-ceiling windows. The journey to the world-famous 86th Floor Observatory, the only 360-degree, open-air observatory with views of New York and beyond, orients visitors for their entire New York City experience and covers everything from the building's iconic history to its current place in pop culture. The Empire State Building Observatory Experience welcomes millions of visitors each year and is ranked the #1 Top Attraction in New York City for the fourth consecutive year in Tripadvisor’s 2025 Travelers’ Choice Awards: Best of the Best Things to Do, "America's Favorite Building" by the American Institute of Architects, the world's most popular travel destination by Uber, and the #1 New York City attraction in Lonely Planet’s Ultimate Travel List.

Since 2011, the building has been fully powered by renewable wind electricity, and its many floors house a diverse array of office tenants such as LinkedIn and Shutterstock, as well as retail options like STATE Grill and Bar, Tacombi, and Starbucks. For more information and Observatory Experience tickets visit esbnyc.com or follow the building's Facebook, X (formerly Twitter), Instagram, Weibo, YouTube, or TikTok.

Source: Empire State Realty Trust, Inc.

Category: Observatory

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250825771303/en/

Permalink

https://www.aetoswire.com/en/news/2508202548578

Contacts

MEDIA CONTACT:

Empire State Realty Trust

Jamie Steinberg

212-400-3339

jsteinberg@esrtreit.com

BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million

• Royalty Pharma to acquire rights to BeOne’s royalties on IMDELLTRA® (tarlatamab-dlle) worldwide (ex-China) sales for up to $950 million
• IMDELLTRA is a first-in-class DLL-3 targeting bispecific T-cell engager, indicated for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy

•  

  (BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it has entered into an agreement to sell its royalty rights on the worldwide sales, excluding China, of Amgen’s IMDELLTRA® (tarlatamab-dlle) for up to $950 million to Royalty Pharma (Nasdaq: RPRX).

  Under the terms of the agreement, BeOne will receive an upfront payment of $885 million, with the option to sell remaining royalties within 12 months for up to $65 million. BeOne will share in a portion of the royalty on annual sales above $1.5 billion, and will maintain royalty and all other rights to other assets under the terms of the existing collaboration with Amgen, including xaluritamig, a first-in-class STEAP1 x CD3 XmAb currently being studied in patients with metastatic castration-resistant prostate cancer (mCRPC).

  IMDELLTRA is a first-in-class immunotherapy that binds to both DLL3 on tumor cells and CD3 on T cells, activating T cells to kill DLL3-expressing cells. IMDELLTRA is approved in the United States for patients with extensive-stage small cell lung cancer (ES-SCLC) who have progressed on or after receiving platinum-based chemotherapy.

  “Today’s announcement is testament to the value of our long-term collaboration with Amgen, the developer of IMDELLTRA, who recognized the potential of BeOne in advancing their oncology pipeline,” said John V. Oyler, Co-Founder, Chairman and CEO of BeOne. “In the five years since entering into this collaboration, we have executed with purpose in advancing our mission to deliver multiple transformative medicines to more patients worldwide.”

  “This agreement meaningfully accelerates value realization for BeOne, while preserving continued participation in the long-term potential of IMDELLTRA,” said Aaron Rosenberg, Chief Financial Officer, BeOne. “A strong balance sheet is a hallmark of the most successful companies in our industry, and this transaction provides increased operational and strategic flexibility as we continue to execute our business strategy for the long term.”

  About IMDELLTRA® (tarlatamab-dlle)

  IMDELLTRA is a first-in-class immunotherapy that binds to both DLL3 on tumor cells and CD3 on T cells, activating T cells to kill DLL3-expressing cells. This results in the formation of a cytolytic synapse with lysis of the cancer cell. DLL3 is a protein that is expressed on the surface of SCLC cells in the vast majority of patients with SCLC, but is minimally expressed on healthy cells, making it an exciting target.

  Tarlatamab is being investigated in multiple studies including DeLLphi-303, a Phase 1b study evaluating tarlatamab in combination with standard of care therapies in first-line ES-SCLC; DeLLphi-304, a randomized Phase 3 trial comparing tarlatamab monotherapy with standard of care chemotherapy in second-line treatment of ES-SCLC; DeLLphi-306, a randomized placebo-controlled Phase 3 trial of tarlatamab following concurrent chemoradiotherapy in limited-stage SCLC; DeLLphi-308, a Phase 1b study evaluating subcutaneous tarlatamab in second line or later ES-SCLC; and DeLLphi-309, a Phase 2 study evaluating alternative intravenous dosing regimens with tarlatamab in second-line ES-SCLC.

  About BeOne Medicines

  BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of more than 11,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them.

  To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.

  Forward-Looking Statement

  This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding: the total amount of proceeds that BeOne will receive from the sale of IMDELLTRA royalty rights; the exercise of BeOne’s option to sell the remaining IMDELLTRA royalty rights; the benefits of the transaction; and BeOne’s plans, commitments, aspirations, and goals under the heading “About BeOne.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeOne's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne's reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeOne’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law.

  To access BeOne media resources, please visit our Newsroom site.

   

  View source version on businesswire.com: https://www.businesswire.com/news/home/20250825210828/en/

  
  
  Permalink
  https://aetoswire.com/en/news/2508202548574
  
  

Contacts

• Investor Contact
  Liza Heapes
  +1 857-302-5663
  ir@beonemed.com

  Media Contact
  Navneet Miller
  +1 857-301-6440
  media@beonemed.com